Halozyme Therapeutics, Inc. (0J2O.L)
USD 48.78
(0.12%)
USD 48.78
(0.12%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.49 Billion USD | 0.43% |
| 2022 | 1.49 Billion USD | 89.62% |
| 2021 | 787.25 Million USD | 22613.65% |
| 2020 | 3.46 Million USD | -99.1% |
| 2019 | 383.04 Million USD | 998.37% |
| 2018 | 34.87 Million USD | -72.13% |
| 2017 | 125.14 Million USD | -37.19% |
| 2016 | 199.22 Million USD | 612.27% |
| 2015 | 27.97 Million USD | -43.9% |
| 2014 | 49.86 Million USD | 0.18% |
| 2013 | 49.77 Million USD | 59.98% |
| 2012 | 31.11 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | 0.0% |
| 2002 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1.5 Billion USD | 0.11% |
| 2024 Q2 | 1.5 Billion USD | 0.11% |
| 2024 Q3 | 1.5 Billion USD | 0.11% |
| 2023 Q4 | 1.49 Billion USD | 0.11% |
| 2023 Q2 | 1.49 Billion USD | 0.11% |
| 2023 Q1 | 1.49 Billion USD | 0.11% |
| 2023 Q3 | 1.49 Billion USD | 0.11% |
| 2023 FY | 1.49 Billion USD | 0.43% |
| 2022 FY | 1.49 Billion USD | 89.62% |
| 2022 Q4 | 1.49 Billion USD | 0.11% |
| 2022 Q1 | 788.09 Million USD | 0.11% |
| 2022 Q2 | 1.14 Billion USD | 45.56% |
| 2022 Q3 | 1.49 Billion USD | 29.99% |
| 2021 Q2 | 785.57 Million USD | 0.11% |
| 2021 Q1 | 784.73 Million USD | 22540.83% |
| 2021 Q4 | 787.25 Million USD | 0.1% |
| 2021 Q3 | 786.45 Million USD | 0.11% |
| 2021 FY | 787.25 Million USD | 22613.65% |
| 2020 Q1 | 386.57 Million USD | 0.92% |
| 2020 Q3 | 393.63 Million USD | 0.91% |
| 2020 Q4 | 3.46 Million USD | -99.12% |
| 2020 FY | 3.46 Million USD | -99.1% |
| 2020 Q2 | 390.07 Million USD | 0.91% |
| 2019 Q4 | 383.04 Million USD | 4015.22% |
| 2019 FY | 383.04 Million USD | 998.37% |
| 2019 Q3 | 9.3 Million USD | -33.91% |
| 2019 Q2 | 14.08 Million USD | -24.86% |
| 2019 Q1 | 18.74 Million USD | -46.26% |
| 2018 FY | 34.87 Million USD | -72.13% |
| 2018 Q4 | 34.87 Million USD | -39.81% |
| 2018 Q3 | 57.94 Million USD | -26.73% |
| 2018 Q2 | 79.08 Million USD | -23.0% |
| 2018 Q1 | 102.69 Million USD | -17.94% |
| 2017 Q2 | 165.51 Million USD | -10.25% |
| 2017 FY | 125.14 Million USD | -37.19% |
| 2017 Q1 | 184.43 Million USD | -7.43% |
| 2017 Q4 | 125.14 Million USD | -13.94% |
| 2017 Q3 | 145.41 Million USD | -12.14% |
| 2016 Q4 | 199.22 Million USD | -0.29% |
| 2016 FY | 199.22 Million USD | 612.27% |
| 2016 Q2 | 204.85 Million USD | 21.5% |
| 2016 Q1 | 168.6 Million USD | 502.77% |
| 2016 Q3 | 199.8 Million USD | -2.46% |
| 2015 FY | 27.97 Million USD | -43.9% |
| 2015 Q3 | 34.09 Million USD | -14.97% |
| 2015 Q1 | 45.98 Million USD | -7.77% |
| 2015 Q2 | 40.09 Million USD | -12.8% |
| 2015 Q4 | 27.97 Million USD | -17.96% |
| 2014 FY | 49.86 Million USD | 0.18% |
| 2014 Q2 | 43.61 Million USD | -7.97% |
| 2014 Q3 | 39.76 Million USD | -8.83% |
| 2014 Q1 | 47.38 Million USD | -4.79% |
| 2014 Q4 | 49.86 Million USD | 25.4% |
| 2013 Q4 | 49.77 Million USD | 89.02% |
| 2013 Q2 | 28.17 Million USD | -5.37% |
| 2013 Q1 | 29.77 Million USD | -4.3% |
| 2013 FY | 49.77 Million USD | 59.98% |
| 2013 Q3 | 26.33 Million USD | -6.54% |
| 2012 FY | 31.11 Million USD | 0.0% |
| 2012 Q4 | 31.11 Million USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2003 Q4 | - USD | 0.0% |
| 2003 Q3 | - USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| 2003 Q1 | - USD | 0.0% |
| 2003 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q4 | - USD | 0.0% |
| 2002 FY | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -6051.518% |
| Dynavax Technologies Corporation | 252.41 Million USD | -493.954% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -4416.351% |
| Perrigo Company plc | 3.63 Billion USD | 58.73% |
| Illumina, Inc. | 1.48 Billion USD | -0.688% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 95.211% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -149824.8% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 81.362% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 88.427% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -762.862% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 44.532% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -6269.209% |
| Waters Corporation | 2.3 Billion USD | 34.971% |
| Biogen Inc. | 7.18 Billion USD | 79.143% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -4373.364% |
| Evolus, Inc. | 120.35 Million USD | -1145.647% |
| Adicet Bio, Inc. | 17.7 Million USD | -8368.892% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -3943.388% |
| bluebird bio, Inc. | 224.41 Million USD | -568.058% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -198.925% |
| FibroGen, Inc. | 89.69 Million USD | -1571.458% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 45.183% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -46192.646% |
| Homology Medicines, Inc. | 43.17 Million USD | -3372.411% |
| Geron Corporation | 35.05 Million USD | -4177.333% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 36.012% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -286.546% |
| Myriad Genetics, Inc. | 130.9 Million USD | -1045.338% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -160076.068% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -1449.658% |
| Zoetis Inc. | 6.56 Billion USD | 77.16% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -33958.337% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 24.11% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -152.784% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -106.878% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -4285.048% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -7.06% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -3181.133% |
| Verastem, Inc. | 40.08 Million USD | -3640.079% |
| Nektar Therapeutics | 112.62 Million USD | -1231.186% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -741.943% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -48671.893% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -32.382% |
| OPKO Health, Inc. | 222.03 Million USD | -575.234% |
| Exelixis, Inc. | 189.94 Million USD | -689.311% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -480.429% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | -1052.691% |
| Imunon, Inc. | 1.13 Million USD | -131494.594% |
| Blueprint Medicines Corporation | 610.96 Million USD | -145.391% |
| Insmed Incorporated | 1.19 Billion USD | -25.633% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -2530.814% |
| TG Therapeutics, Inc. | 100.11 Million USD | -1397.481% |
| Incyte Corporation | 29.16 Million USD | -5041.101% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -235.778% |